Magnus Jaderberg
Technik-/Wissenschafts-/F&E-Leiter bei Targovax Oy
Aktive Positionen von Magnus Jaderberg
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Targovax Oy
 Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
| King's College (Pennsylvania) | Corporate Officer/Principal | - | - |
| Karolinska Institutet | Corporate Officer/Principal | - | - |
| The Royal College of Physicians | Corporate Officer/Principal | - | - |
Karriereverlauf von Magnus Jaderberg
Ehemalige bekannte Positionen von Magnus Jaderberg
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
| CIRCIO HOLDING ASA | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Statistik
International
| Vereinigte Staaten | 3 |
| Finnland | 2 |
| Schweden | 2 |
Operativ
| Corporate Officer/Principal | 4 |
| Chief Tech/Sci/R&D Officer | 2 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CIRCIO HOLDING ASA | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Health Technology |
- Börse
- Insiders
- Magnus Jaderberg
- Erfahrung
